b-701
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02401542)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Receptor, Fibroblast Growth Factor, Type 3 · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Urinary Bladder Diseases · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Urologic Diseases · Phase 1/Phase 2
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297848 ↗
Also known as
- b-701
- b-701
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05363605 | Phase 1/Phase 2 (Phase 2) | Apr 20, 2022 | Fusion Pharma LLC |
| NCT03123055 | Phase 1 | Apr 20, 2017 | Rainier Therapeutics |
| NCT02925533 | Phase 1 | Dec 14, 2016 | Harvard University, Merck, Rainier Therapeutics |
| NCT02401542 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2015 | Rainier Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rainier Therapeutics | For profit | 3 | 2 | 2 | 2015 |
| Fusion Pharma LLC | For profit | 1 | 1 | 1 | 2022 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Merck | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1